Loading company…
Rapafusyn Pharmaceuticals develops macrocyclic peptide libraries and drug discovery tools.
Rapafusyn provides FKBP-binding macrocyclic peptides, DNA-encoded libraries and molecular glue libraries for drug discovery targeting intracellular and transmembrane proteins. Its services include rapid structure-activity relationship expansion. Founded in 2015, the company is based in Baltimore, US. In September 2025, it raised USD 44 million in Series A funding from 3E Bioventures Capital, Proxima Ventures, Lapam Capital, Yongjin Group and BioTrack Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in